Objective To study the mechanism of heat transfer by simulating a complete freezing-thawing process of biological tissue.Methods A numerical model of phase change heat transfer in biological tissue was developed with consideration of the difference of thermophysical properties for normal biological tissue and tumor.The biological tissue was assumed as a porous media.The different thermophysical properties between tissue framework and tissue fluid(as water in tissue,etc) were considered.An apparent heat capacity method was applied to solve the phase change heat transfer problem.Results It was showed that the temperature of biological tissue decreased more quickly during the freezing process when the initial cryoprobe temperature was lower and the cooling-rate of cryoprobe was faster.The temperature of biological tissue increased more quickly with faster warming-rate of cryoprobe in the thawing process.It was also showed that the porosity,blood perfusion rate and metabolic heat generation of the biological tissue had effects on tissue freezing temperature in biological tissue.Conclusion To study the thermal process of biological tissue in cryosurgery will be very helpful for further application in cryosurgery.

Objective To investigate the clinical efficacy of Shenqi Fuzheng injection and chemotherapy in elderly patients with non-small cell lung cancer(NSCLC),and to observe its effect on immune function and serum tumor markers of carcino embryonie antigen(CEA),carbohydrate antigen 19-9(CA19-9),cytokeratin 19 fragment(CYFRA21-1)and neuronspecific enolase(NSE).Methods 80 patients with NSCLC who were confirmed as non-small cell lung cancer were enrolled in the study.Among them,the control group received paclitaxel + carboplatin chemotherapy,40 patients; the treatment group received Shenqi Fuzheng injection on the basis of the control group,40 cases.The clinical curative effect was evaluated after four cycles of treatment and the adverse reactions were recorded.The scores of traditional Chinese medicine(TCM)syndrome before and after four cycles of treatment were evaluated,and the quality of life of the patients before and after treatment were evaluated by Karnofsky performance score(KPS).The immune function and tumor markers were measured before and after treatment.Results The total effective rate of the treatment group was 65.0％,which was significantly higher than that of the control group(42.5％,χ2=4.07,P=0.04).In the treatment group,the adverse reaction rate was 37.5％,significantly lower than 62.5％in the control group(χ2=5.00,P=0.02).The score of TCM syndrome in the two groups was significantly lower than that in the control group before treatment,and the KPS score was significantly higher than that in the control group before treatment,the score of TCM syndrome in the treatment group was significantly lower than that in the control group(P<0.05).After treatment,the immune function of patients in the treatment group compared with before treatment had no significant difference,while the control group after treatment of the immune function was significantly lower than before treatment,and compared with the treatment group(P<0.05).The two groups of patients after treatment of tumor markers decreased significantly,and the treatment group decreased significantly compared with the control group(P<0.05).Conclusion Supplemented with Shenqi Fuzheng injection in the treatment of elderly non-small cell lung cancer on the immune function of little effect,help to promote serum levels of serum tumor markers and clinical symptoms improved,reduce adverse reactions,improve clinical efficacy and quality of life.

Objective To observe the change of regulatory T cells expression in severely burned rats gut ,To investigate the effects of regulatory T cells on CD3+CD4+ /CD3+CD8+lymphocytes and its relation with gut-origin endotoxin translocation .Meth-ods Fifty SD male rats were randomly divided into normal control group(n=10)and burn model groups(n=40) .Rats were burned to achieve Ⅲ degree scalding ,and a 30% total body surface area(TBSA) burn model was made .Rats were sacrificed before(normal control group) and after 0 .5 ,1 ,2 ,4 burn hour(PBH groups) .Flow cytometry techniques were used for the detection of the expres-sions of regulatory T cells and CD3+CD4+ /CD3+CD8+ lymphocyte in intestinal lymph nodes which were separated .The dynamic turbidity method was used for detection of endotoxin levels in portal vein blood .Results The expression of regulatory T cells was negativelycorrelatedwithCD3+CD4+ /CD3+CD8+ lymphocyteratio(r= -0.827,P<0.01)inintestinallymphnodeofrats,while the regulatory T cells was positively correlated with ET levels in portal vein blood plasma .(r=0 .782 ,P<0 .01) .Conclusion The expression of the regulatory T cells in intestinal lymph node in severely burned rats was increased compared to that in normal con-trol group .Regulatory T cells suppressed the expression of intestinal T lymphocytes ,leading to gut immune inhibition .The translo-cation of intestinal endotoxin has a close relationship with regulatory T cells in severely burned rats .Regulatory T cells could have portal effects on intestinal immunity barrier .

Objective To investigate the prevalence of hyperuricemia (HUA) in the elderly in Tanggu Community of Tianjin,and to analyze the related factors.Methods The elderly inhabitants from one community of Tanggu in Tianjin were randomly selected and their serum uric acid (SUA)levels and metabolic syndrome (MS)-related indexes were examined.There were 622 subjects with complete data (260 men,362 women; mean age 67.4 ± 6.0 years).Results The standardized prevalence of HUA in the elderly in this community was 9.1％ in total,and 7.6％ in males,10.6％ in females,and there was no significant difference between males and females (P=0.281).The levels of SUA were (283.37 ± 78.69) μmol/L in total,(315.80 ± 74.39) μmol/L in males and (260.00 ±73.31) μmol/L in females,and the SUA level was higher in males than in females (P＜0.001).The levels of blood urea,creatinine (Cr),triglyceride (TG),body mass index (BMI) were higher in patients with HUA than in patients with normal serum uric acid (P=0.000,0.000,0.002,0.049respectively).The multiple factors regression analysis showed that the SUA level was positively correlated with the levels of blood urea,Cr,TG,low density lipoprotein cholesterol (LDL-C) (P=0.000,0.017,0.000,0.019) and was negatively correlated with the levels of high density lipoprotein cholesterol (HDL-C) and fasting blood glucose (P=0.000,0.001).Conclusions The prevalence of HUA in the elderly is lower in Tanggu Community of Tianjin than in other cities in China.The SUA level of the elderly is significant higher in males than in females.The lower kidney function,hypertriglyceridemia and higher LDL-C are the risk factors for HUA,while elevated HDL-C and fasting blood glucose are associated with the decreased SUA level.

Objective To evaluate the curative effect of transcatheter arterial chemoembolization (TACE) combined with intensity modulated radiation therapy (IMRT) in treating advanced hepatocellular carcinoma (HCC),and to discuss the occurrence of adverse events.Methods A total of 59 patients with advanced HCC were enrolled in this study.The patients were randomly divided into TACE plus IMRT group (study group,n=30) and TACE group (control group,n=29).The early tumor response rate,progression free survival (PFS),median survival time (mST),and adverse reactions were analyzed.Results The early tumor response rate in the study group was 60.0％,which was significantly higher than 34.4％ in the control group (P=0.043).PFS of the study group was 260 days,which was remarkably higher than 195 days of the control group (P=0.006).The mST was 468 days in the study group,which was 431 days in the control group (P=0.195).In the study group,2 patients developed severe liver function damage,which was improved after active liver protection therapy for more than 20 days.Conclusion For the treatment of advanced HCC,TACE combined with IMRT can improve early tumor response rate and prolong PFS time,moreover,its adverse reactions can be well tolerated by patients.

Objective To investigate the distribution of TCR Vβ genealogy and clonal expansion in peripheral blood after infusing mesenchymal stem cells (MSC) in patients with chronic GVHD. Methods The complementarity determining region 3 (CDR3) of 24 TCR Vβ subfamily genes in peripheral blood mononuclear cell from 1 case with cGVHD after allogeneic hematopoietic stem cell transplantation (Allo-HSCT),who were treated with infusing MSC,were amplified using RT-PCR. The blood samples were taken at the first and the fifth day after 1st infusion; and the first day,the 10 th day and the 20 th day after the second infusion of MSC,as well as the MSC infused as control . The products were labelled by fluorescein and then analyzed the CDR3 size with gene scan technique to determine the clonality of T cells. Results There were no expression of TCR Vβ subfamily with the MSC infused and after the 1st day of the first infusion of MSC. Then 3,10,14,10 Vβ subfamilies clones are appeared at the other time points,of which were polyclone and oligoclone predominately. In the same time,the manifestations of cCVHD have been abated. Conclusion MSC played a certain role in reviving the immune function of the patients after Allo-HSCT and mitigating the disease of chronic GVHD. Lineage analysis of TCR Vβ subfamily showed some predominant expression.

Clinical data of 380 patients with type 2 diabetes mellitus (T2DM) admitted in the Second Hospital of Tianjin Medical University from October 2014 to June 2017 were retrospectively reviewed. Patients were divided into 3 groups according to the results of lower extremity arterial ultrasonography: 103 patients without lower extremity arterial disease (group A), 132 patients with mild arterial disease (group B), 145 patients with moderate to severe lower extremity arterial disease (group C);and 100 healthy subjects served as control group. Blood routine parameters and blood biochemistry were measured;the results showed that blood cell ratios in T2DM patients were significantly higher than those in control group (P<0.05), and blood cell ratios in group B and group C were higher than those in group A (P<0.05). Pearson correlation analyses indicated that neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), hs-CRP, HbA1c, LDL-C were significantly associated with lower extremity arterial disease in T2DM patients. Logistic analysis showed that NLR(OR=2.01,95％CI:1.15-3.63,P<0.05)and PLR(OR=1.75,95％CI:1.04-3.28,P<0.05)were risk factors for lower extremity arterial disease in patients with type 2 diabetes mellitus.

Objective:To evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection in the treatment of peripheral T-cell lymphoma (PTCL) in a real-world setting.Methods:This was a real-world ambispective cohort study (MOMENT study) (Chinese clinical trial registry number: ChiCTR2200062067). Clinical data were collected from 198 patients who received mitoxantrone hydrochloride liposome injection as monotherapy or combination therapy at 37 hospitals from January 2022 to January 2023, including 166 patients in the retrospective cohort and 32 patients in the prospective cohort; 10 patients in the treatment-na?ve group and 188 patients in the relapsed/refractory group. Clinical characteristics, efficacy and adverse events were summarized, and the overall survival (OS) and progression-free survival (PFS) were analyzed.Results:All 198 patients were treated with mitoxantrone hydrochloride liposome injection for a median of 3 cycles (range 1-7 cycles); 28 cases were treated with mitoxantrone hydrochloride liposome injection as monotherapy, and 170 cases were treated with the combination regimen. Among 188 relapsed/refractory patients, 45 cases (23.9%) were in complete remission (CR), 82 cases (43.6%) were in partial remission (PR), and 28 cases (14.9%) were in disease stabilization (SD), and 33 cases (17.6%) were in disease progression (PD), with an objective remission rate (ORR) of 67.6% (127/188). Among 10 treatment-na?ve patients, 4 cases (40.0%) were in CR, 5 cases (50.0%) were in PR, and 1 case (10.0%) was in PD, with an ORR of 90.0% (9/10). The median follow-up time was 2.9 months (95% CI 2.4-3.7 months), and the median PFS and OS of patients in relapsed/refractory and treatment-na?ve groups were not reached. In relapsed/refractory patients, the difference in ORR between patients with different number of treatment lines of mitoxantrone hydrochloride liposome injection [ORR of the second-line, the third-line and ≥the forth-line treatment was 74.4% (67/90), 73.9% (34/46) and 50.0% (26/52)] was statistically significant ( P = 0.008). Of the 198 PTCL patients, 182 cases (91.9%) experienced at least 1 time of treatment-related adverse events, and the incidence rate of ≥grade 3 adverse events was 66.7% (132/198), which was mainly characterized by hematologic adverse events. The ≥ grade 3 hematologic adverse events mainly included decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, and anemia; non-hematologic adverse events were mostly grade 1-2, mainly including pigmentation disorders and upper respiratory tract infection. Conclusions:The use of mitoxantrone hydrochloride liposome injection-containing regimen in the treatment of PTCL has definite efficacy and is well tolerated, and it is a new therapeutic option for PTCL patients.